



All Databases

Search PubMed

**PubMed**  
www.pubmed.gov

A service of the National Library of Medicine  
and the National Institutes of Health

PubMed  
for

Nucleotide

Protein

Genome

Structure

OMIM

PMC

Journals

Books

My NCBI [2]  
[Sign In] [Register]

☒ Limits ☒ Preview/Index ☒ History ☒ Clipboard ☒ Details

Go Clear

Limits: Publication Date from 2005 to 2005

About Entrez

☐ 1: [Int J Oncol.](#) 2005 Nov;27(5):1257-63.

Text Version

Related Articles, Links

Entrez PubMed

Overview

Help | FAQ

Tutorials

New/Noteworthy

E-Utilities



PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

Special Queries

LinkOut

My NCBI

Related Resources

Order Documents

NLM Mobile

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

## Expression of human telomerase reverse transcriptase gene and protein, and of estrogen and progesterone receptors, in breast tumors: preliminary data from neo-adjuvant chemotherapy.

Kammori M, Izumiyama N, Hashimoto M, Nakamura K, Okano T, Kurabayashi R, Naoki H, Honma N, Ogawa T, Kaminishi M, Takubo K.

Division of Breast and Endocrine Surgery, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Japan. [kanmori-dis@umin.ac.jp](mailto:kanmori-dis@umin.ac.jp)

Human telomerase reverse transcriptase (hTERT), the catalytic subunit of telomerase, is very closely associated with telomerase activity. Telomerase has been implicated in cellular immortalization and carcinogenesis. In situ detection of hTERT will aid in determining the localization of telomerase-positive cells. The aim of this study was to detect expression of hTERT mRNA, hTERT protein, estrogen receptor (ER) and progesterone receptor (PR) in paraffin-embedded breast tissue samples and to investigate the relationship between hTERT expression and various clinicopathological parameters in breast tumorigenesis. We used in situ hybridization (ISH) to examine hTERT gene expression, and immunohistochemistry (IHC) to examine expression of hTERT protein, ER and PR, in breast tissues including 64 adenocarcinomas, 2 phyllode tumors and their adjacent normal breast tissues. hTERT gene expression was detected by ISH in 52 (81%) carcinomas, but in neither of the 2 phyllode tumors. hTERT protein expression was detected by IHC in 52 (81%) carcinomas, but in neither of the 2 phyllode tumors. Moreover, ER and PR were expressed in 42 (66%) and 42 (66%) carcinomas, respectively, and in neither of the 2 phyllode tumors. In 4 cases of breast carcinoma that strongly expressed hTERT gene and protein before treatment, neo-adjuvant chemotherapy led to disappearance of gene and protein expression in all cases. There was a strong correlation between detection of hTERT gene expression by ISH and of hTERT protein by ICH in tissue specimens from breast tumors. These results suggest that detection of hTERT protein by ICH can be used to distinguish breast cancers as a potential diagnostic and therapeutic marker.

PMID: 16211220 [PubMed - indexed for MEDLINE]

---

Jun 14 2006 10:29:54